NCT01563562View on ClinicalTrials.gov

Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Hepatic ImpairmentHealthy
Interventions
DRUG

Bardoxolone Methyl

Oral, Single dose

Trial Locations (2)

27710

Duke University, Durham

33136

University of Miami School of Medicine, Miami

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY

NCT01563562 - Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function | Biotech Hunter | Biotech Hunter